Cwm LLC Has $8.05 Million Stock Position in Zoetis Inc. $ZTS

Cwm LLC raised its position in shares of Zoetis Inc. (NYSE:ZTS) by 53.2% in the third quarter, HoldingsChannel.com reports. The firm owned 55,040 shares of the company’s stock after purchasing an additional 19,118 shares during the quarter. Cwm LLC’s holdings in Zoetis were worth $8,053,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Vanguard Group Inc. increased its position in shares of Zoetis by 0.8% during the second quarter. Vanguard Group Inc. now owns 41,886,987 shares of the company’s stock worth $6,532,276,000 after buying an additional 330,823 shares during the period. Geode Capital Management LLC lifted its holdings in Zoetis by 0.9% in the second quarter. Geode Capital Management LLC now owns 11,081,301 shares of the company’s stock valued at $1,721,356,000 after buying an additional 95,294 shares during the period. Norges Bank bought a new stake in Zoetis during the second quarter valued at $809,491,000. Brown Advisory Inc. grew its holdings in Zoetis by 5.7% during the 2nd quarter. Brown Advisory Inc. now owns 4,659,371 shares of the company’s stock worth $726,629,000 after acquiring an additional 250,829 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of Zoetis by 4.3% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,252,697 shares of the company’s stock worth $700,207,000 after acquiring an additional 174,119 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently commented on ZTS. BTIG Research restated a “buy” rating and set a $160.00 target price on shares of Zoetis in a research report on Wednesday, December 3rd. HSBC set a $140.00 price target on Zoetis in a report on Wednesday, December 10th. JPMorgan Chase & Co. lowered their price objective on shares of Zoetis from $230.00 to $200.00 and set an “overweight” rating for the company in a research note on Wednesday, November 5th. Weiss Ratings lowered shares of Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Tuesday, December 23rd. Finally, Stifel Nicolaus reduced their price target on shares of Zoetis from $140.00 to $130.00 and set a “hold” rating for the company in a report on Tuesday, November 18th. Six analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $160.18.

Zoetis Price Performance

Shares of NYSE:ZTS opened at $125.90 on Tuesday. Zoetis Inc. has a twelve month low of $115.25 and a twelve month high of $177.40. The stock’s 50 day moving average is $126.66 and its 200-day moving average is $142.51. The company has a quick ratio of 2.28, a current ratio of 3.64 and a debt-to-equity ratio of 1.31. The firm has a market capitalization of $55.48 billion, a price-to-earnings ratio of 21.19, a PEG ratio of 2.74 and a beta of 0.97.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Tuesday, November 4th. The company reported $1.70 EPS for the quarter, beating analysts’ consensus estimates of $1.62 by $0.08. Zoetis had a net margin of 28.21% and a return on equity of 57.19%. The business had revenue of $2.40 billion during the quarter, compared to analyst estimates of $2.42 billion. During the same quarter in the previous year, the business posted $1.58 EPS. Zoetis’s quarterly revenue was up .5% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Sell-side analysts forecast that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 3rd. Stockholders of record on Tuesday, January 20th will be given a dividend of $0.53 per share. The ex-dividend date of this dividend is Tuesday, January 20th. This is a boost from Zoetis’s previous quarterly dividend of $0.50. This represents a $2.12 annualized dividend and a dividend yield of 1.7%. Zoetis’s payout ratio is presently 33.67%.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.